AstraZeneca presents positive results from Phase III POSEIDON trial for NSCLC
AstraZeneca announced that its Imfinzi (durvalumab) and tremelimumab have demonstrated positive progression-free survival (PFS) results in the Phase III POSEIDON trial. The POSEIDON trial is a randomised, open-label,